Campaign Speaks to Undiagnosed and Diagnosed
"Internal Agonizers"
- Campaign tells men who are endlessly searching online
for answers to stop typing and start talking to a specialized
urologist about Peyronie's disease
- Commercial and
ads address men's embarrassment, reluctance and fear in talking
about their symptoms and seeking treatment
DUBLIN, Feb. 6, 2023 /PRNewswire/ -- Endo International
plc (OTC: ENDPQ) announced today the launch of the "Man With a
Plan" campaign, which aims to motivate men who may have symptoms of
Peyronie's disease (PD) to go to MakeaPDplan.com to find a
specialized urologist who can diagnose and treat them. PD is a
men's health condition that is estimated to affect 1 in 10 men in
the U.S.* and can lead to a curvature deformity of the penis when
erect.
"The campaign speaks directly to internal agonizers—those men
who are searching online and have unanswered questions about PD,"
said Gregory Thomas, Senior
Director, Men's Health Marketing at Endo. "With understanding and
empathy, we're sending a clear message: Make a plan to talk to a
specialized urologist."
The 30-second commercial opens with scenes of men searching
online for answers to their PD-related questions, illustrating the
confusion, stress and loneliness felt by the internal agonizers.
The call to action follows the montage: "Stop typing. Start
talking—to a specialized urologist." There's data-backed reasoning
that Endo wants patients to move on from their solo research.
"Endo's own market research confirms that the journey to
treatment for men with PD can take years," added Dayna Sracic, Senior Director, Consumer
Marketing at Endo. "Embarrassment about the condition, fear of
treatments and the 'wait and see' approach contribute to the long
timeline. 'Man With a Plan' helps activate men to break that cycle
and advocate for their health."
The "Man With a Plan" campaign will run on TV, online and on
social media channels, as well as through materials in doctors'
offices—all driving to MakeaPDplan.com.
* Based on a survey of about 7,700 U.S. adult men with a PD
diagnosis, PD-related symptoms or a history of seeking treatment
for the condition.
About Peyronie's Disease
Peyronie's disease (PD) is a
condition in which a buildup of fibrous scar tissue causes a
curvature deformity of the penis. This curvature can be painful
during arousal and intimacy. PD can affect as many as 1 in 10 men
in the U.S., but diagnosis rates remain low because men with PD may
be too uncomfortable to speak up and get help.
About Endo
Endo (OTC: ENDPQ) is a specialty
pharmaceutical company committed to helping everyone we serve live
their best life through the delivery of quality, life-enhancing
therapies. Our decades of proven success come from passionate team
members around the globe collaborating to bring treatments forward.
Together, we boldly transform insights into treatments benefiting
those who need them, when they need them. Learn more
at www.endo.com or connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking
Statements
Certain information in this press release may be
considered "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 and any applicable
Canadian securities legislation, including, but not limited to, the
statements by Mr. Thomas and Ms. Sracic, any statements related to
the Company's campaigns and any statements that refer to expected,
estimated or anticipated future results or that do not relate
solely to historical facts. Statements including words or phrases
such as "believe," "expect," "anticipate," "intend," "estimate,"
"plan," "will," "may," "look forward," "intend," "guidance,"
"future," "potential" or similar expressions are forward-looking
statements. All forward-looking statements in this communication
reflect the Company's current views as of the date of this
communication about its plans, intentions, expectations, strategies
and prospects, which are based on the information currently
available to it and on assumptions it has made. Actual results may
differ materially and adversely from current expectations based on
a number of factors, including, among other things, the outcome of
the Company's contingency planning and restructuring activities;
the timing, impact or results of any pending or future litigation,
investigations, proceedings or claims, including opioid, tax and
antitrust related matters; any actual or contingent liabilities;
settlement discussions or negotiations; the Company's liquidity,
financial performance, cash position and operations; the risks and
uncertainties associated with chapter 11 proceedings; the negative
impacts on the Company's businesses as a result of filing for and
operating under chapter 11 protection; the time, terms and ability
to confirm a sale of the Company's businesses under Section 363 of
the U.S. Bankruptcy Code; the risk that the Company's chapter 11
cases may be converted to cases under Chapter 7 of the Bankruptcy
Code; the adequacy of the capital resources of the Company's
businesses and the difficulty in forecasting the liquidity
requirements of the operations of the Company's businesses; the
unpredictability of the Company's financial results while in
chapter 11 proceedings; the Company's ability to discharge claims
in chapter 11 proceedings; negotiations with the holders of the
Company's indebtedness and its trade creditors and other
significant creditors; and risks and uncertainties with performing
under the terms of the restructuring support agreement and any
other arrangement with lenders or creditors while in chapter 11
proceedings. The Company expressly disclaims any intent or
obligation to update these forward-looking statements, except as
required to do so by law.
Additional information concerning risk factors, including those
referenced above, can be found in press releases issued by the
Company, as well as the Company's public periodic filings with the
U.S. Securities and Exchange Commission and with securities
regulators in Canada, including
the discussion under the heading "Risk Factors" in the Company's
most recent Annual Report on Form 10-K and any subsequent Quarterly
Reports on Form 10-Q or other filings with the U.S. Securities and
Exchange Commission. Copies of the Company's press releases and
additional information about the Company are available at
www.endo.com or you can contact the Company's Investor Relations
Department at relations.investor@endo.com.
Logo -
https://mma.prnewswire.com/media/530208/Endo_International_plc_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/endo-launches-man-with-a-plan-campaign-to-support-men-with-symptoms-of-peyronies-disease-301738966.html
